Cingulate

Cingulate EPS

The Earnings per Share (EPS) of Cingulate (CING) as of Nov 11, 2026 is -4.13 USD. In the previous year, Earnings per Share (EPS) was -4.87 USD — a change of -15.07% (higher).

EPS

-4.13USD

YoY

-15.07%

Last updated:

Earnings per Share (EPS) of Cingulate is 2025 -4.13 USD. Earnings per Share (EPS) of Cingulate was 2024 -4.87 USD. It decreases by -15.07% higher compared to the previous year.

The Cingulate EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2023
-241.88 USD
Jan 1, 2024
-4.87 USD
Jan 1, 2025
-4.13 USD
Jan 1, 2026 (e)
-2.13 USD
Jan 1, 2027 (e)
-1.75 USD
Jan 1, 2028 (e)
-1.17 USD
Jan 1, 2029 (e)
-0.41 USD
Jan 1, 2030 (e)
0.66 USD
The Cingulate EPS history
YEAREPSYoY
est0.66USD-260.98%
est-0.41USD-64.96%
est-1.17USD-33.24%
est-1.75USD-17.82%
est-2.13USD-48.41%
-4.13USD-15.07%
-4.87USD-97.99%
-241.88USD+1,815.64%
-12.63USD-37.28%
-20.13USD+296.19%
-5.08USD+139.02%
-2.13USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Earnings per Share (EPS) of Cingulate is -4.13 USD in 2025.

Earnings per Share (EPS) of Cingulate changed from -4.87 USD to -4.13 USD, representing a -15.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Cingulate since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cingulate

All Key Metrics — Cingulate